002422 Share Price Performance
CN¥34.57
-1.18 (-3.30%)
11.4% undervalued intrinsic discount
CN¥39.00
Fair Value
Price CN¥34.57
AnalystConsensusTarget CN¥39.00
AnalystLowTarget CN¥29.00
AnalystHighTarget CN¥47.00
Fair ValueCN¥39.00
Share Pricen/a
Sichuan Kelun Pharmaceutical Co., Ltd. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
002422 Community Narratives
AN
Fair Value
·Fair Value CN¥39 11.4% undervalued intrinsic discount
002422: Rising Profit Margins and Cash Dividend Will Drive Positive Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value CN¥29 19.2% overvalued intrinsic discount
International Regulatory Hurdles And China Pricing Pressure Will Erode Margins
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value CN¥47 26.4% undervalued intrinsic discount
Rising Middle Class And Aging Populations Will Expand Drug Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Rising Middle Class And Aging Populations Will Expand Drug Markets
Key Takeaways Accelerated new therapy launches, global partnerships, and innovative drug focus could drive earnings growth and margin expansion beyond current expectations. Expanding domestic reach and overseas market entry, coupled with policy agility and strong financials, may unlock sustained revenue growth and defensible earnings.Read more
AN
CN¥47
26.4% undervalued intrinsic discount
Fair Value
Revenue
16.44% p.a.
Profit Margin
12.8%
Future PE
24.72x
Price in 2029
CN¥56.93
International Regulatory Hurdles And China Pricing Pressure Will Erode Margins
Key Takeaways Growing pricing pressure, regulatory uncertainties, and rising compliance costs threaten future sales growth, profitability, and international revenue potential. Heavy R&D spending, reliance on legacy products, and tightening ESG requirements may erode market share and strain operational margins over time.Read more
AN
CN¥29
19.2% overvalued intrinsic discount
Fair Value
Revenue
8.71% p.a.
Profit Margin
12.65%
Future PE
18.97x
Price in 2029
CN¥35.13
002422: Rising Profit Margins and Cash Dividend Will Drive Positive Outlook
Key Takeaways Expanding innovative drug pipeline and commercial launches, underpinned by rapid insurance uptake, drive strong growth in recurrent and high-visibility revenues. International partnerships and broad innovation investments enhance earnings potential, margin expansion, and global market presence.Read more
AN
CN¥39
11.4% undervalued intrinsic discount
Fair Value
Revenue
7.21% p.a.
Profit Margin
13.9%
Future PE
26.75x
Price in 2029
CN¥47.22
Trending Discussion
Recently Updated Narratives
AN
002422: Higher P/E Expectations And Completed Buyback Are Expected To Support Upside
Fair Value: CN¥47 26.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
002422: Share Buyback And Lower Future P/E Will Sustain Overvaluation Risk
Fair Value: CN¥29 19.2% overvalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
002422: Share Repurchase And New Agreements Will Support Future Returns
Fair Value: CN¥39 11.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Sichuan Kelun Pharmaceutical Co., Ltd. Key Details
About 002422
- Founded
- 1996
- Employees
- 20127
- CEO
- WebsiteView website
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications. It also provides ambroxol hydrochloride, potassium chloride, sodium chloride, magnesium sulfate, glucose, sterile water, sodium bicarbonate, lidocaine hydrochloride, vitamin B6, ribavirin, ceftazidime, 5% glucose, and ceftriaxone sodium injections. In addition, the company engages in investment; import and export; enterprise management; logistics and transportation; business services; agricultural non-staple food processing; production and sale of pharmaceutical intermediates; research and development of bio-based materials technology; Internet and related services; crop planting; professional technical; biotechnology extension; socio-economic consultation; technology promotion; medical research and testing exhibition; general cargo road transport; ecological protection and environmental management; and wholesale and retail. It exports its products to Japan. The company was formerly known as Sichuan Kelun Pharmaceutical Factory Co., Ltd and changed its name to Sichuan Kelun Pharmaceutical Co., Ltd. in August 2003. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Industry Group CO., LTD.
Recent 002422 News & Updates
